Works by de Vries, Elisabeth G. E.
Results: 171
RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Words Matter: Distinguishing "Personalized medicine" and "Biologically Personalized Therapeutics".
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 12, p. 1, doi. 10.1093/jnci/dju321
- By:
- Publication type:
- Article
Words Matter: Distinguishing "Personalized Medicine" and "Biologically Personalized Therapeutics".
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 12, p. 1, doi. 10.1093/jnci/dju321
- By:
- Publication type:
- Article
Profiling Studies in Ovarian Cancer: A Review.
- Published in:
- Oncologist, 2007, v. 12, n. 8, p. 960, doi. 10.1634/theoncologist.12-8-960
- By:
- Publication type:
- Article
Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: Involvement of AP-1.
- Published in:
- International Journal of Cancer, 1999, v. 81, n. 2, p. 236, doi. 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R
- By:
- Publication type:
- Article
Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent.
- Published in:
- Cell Cycle, 2012, v. 11, n. 24, p. 4552, doi. 10.4161/cc.22803
- By:
- Publication type:
- Article
Variability in responsiveness to lovastatin of the primitive CD34<sup>+</sup> AML subfraction compared to normal CD34<sup>+</sup> cells.
- Published in:
- Annals of Hematology, 2009, v. 88, n. 6, p. 573, doi. 10.1007/s00277-008-0633-2
- By:
- Publication type:
- Article
Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease.
- Published in:
- Human Genetics, 2005, v. 116, n. 4, p. 247, doi. 10.1007/s00439-004-1233-4
- By:
- Publication type:
- Article
Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations.
- Published in:
- Molecular Imaging & Biology, 2023, v. 25, n. 2, p. 435, doi. 10.1007/s11307-022-01775-5
- By:
- Publication type:
- Article
Elevated Urinary Free and Deconjugated Catecholamines after Consumption of a Catecholamine-Rich Diet.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2010, v. 95, n. 6, p. 2851, doi. 10.1210/jc.2009-2589
- By:
- Publication type:
- Article
Dietary Influences on Plasma and Urinary Metanephrines: Implications for Diagnosis of Catecholamine-Producing Tumors.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2009, v. 94, n. 8, p. 2841, doi. 10.1210/jc.2009-0303
- By:
- Publication type:
- Article
Optimisation of scan duration and image quality in oncological <sup>89</sup>Zr immunoPET imaging using the Biograph Vision PET/CT.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 8, p. 2258, doi. 10.1007/s00259-023-06194-4
- By:
- Publication type:
- Article
Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 13, p. 4369, doi. 10.1007/s00259-021-05407-y
- By:
- Publication type:
- Article
Interobserver reproducibility of tumor uptake quantification with <sup>89</sup>Zr-immuno-PET: a multicenter analysis.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2019, v. 46, n. 9, p. 1840, doi. 10.1007/s00259-019-04377-6
- By:
- Publication type:
- Article
Lesion detection by [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2019, v. 46, n. 9, p. 1931, doi. 10.1007/s00259-019-04358-9
- By:
- Publication type:
- Article
Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2018, v. 45, n. 13, p. 2404, doi. 10.1007/s00259-018-4090-4
- By:
- Publication type:
- Article
Clinical-grade N-(4-[<sup>18</sup>F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2019, v. 4, n. 1, p. N.PAG, doi. 10.1186/s41181-019-0062-7
- By:
- Publication type:
- Article
The analysis of longitudinal quality of life measures with informative drop-out: a pattern mixture approach.
- Published in:
- Quality of Life Research, 2010, v. 19, n. 1, p. 137, doi. 10.1007/s11136-009-9564-1
- By:
- Publication type:
- Article
Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 11, p. 12071, doi. 10.1002/cam4.5893
- By:
- Publication type:
- Article
Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.
- Published in:
- Diagnostics (2075-4418), 2024, v. 14, n. 4, p. 416, doi. 10.3390/diagnostics14040416
- By:
- Publication type:
- Article
Analyzing the Estrogen Receptor Status of Liver Metastases with [ 18 F]-FES-PET in Patients with Breast Cancer.
- Published in:
- Diagnostics (2075-4418), 2021, v. 11, n. 11, p. 2019, doi. 10.3390/diagnostics11112019
- By:
- Publication type:
- Article
One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults.
- Published in:
- Clinical Endocrinology, 2000, v. 52, n. 4, p. 457, doi. 10.1046/j.1365-2265.2000.00993.x
- By:
- Publication type:
- Article
The HLA class III subregion is responsible for an increased breast cancer risk.
- Published in:
- Human Molecular Genetics, 2003, v. 12, n. 22, p. 3041, doi. 10.1093/hmg/ddg342
- By:
- Publication type:
- Article
The HLA class III subregion is responsible for an increased breast cancer risk.
- Published in:
- Human Molecular Genetics, 2003, v. 12, n. 18, p. 2311, doi. 10.1093/hmg/ddg245
- By:
- Publication type:
- Article
Calcium or Resistant Starch Does Not Affect Colonic Epithelial Cell Proliferation Throughout the Colon in Adenoma Patients: A Randomized Controlled Trial.
- Published in:
- Nutrition & Cancer, 2002, v. 43, n. 1, p. 31, doi. 10.1207/S15327914NC431_3
- By:
- Publication type:
- Article
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 3, p. 589
- By:
- Publication type:
- Article
Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-<sup>18</sup>F-Fluoro-17β-Fluoroestradiol.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 3, p. 351, doi. 10.2967/jnumed.123.265420
- By:
- Publication type:
- Article
<sup>89</sup>Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted <sup>227</sup>Th-Conjugate Therapy in Mice.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 11, p. 1715, doi. 10.2967/jnumed.121.263079
- By:
- Publication type:
- Article
<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging 1 reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263079
- By:
- Publication type:
- Article
<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263079
- By:
- Publication type:
- Article
<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263079
- By:
- Publication type:
- Article
<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging 1 reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263079
- By:
- Publication type:
- Article
<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263079
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Assessment of Bone Lesions with 18F-FDG-PET Compared to 99mTechnetium Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.244640
- By:
- Publication type:
- Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.241877
- By:
- Publication type:
- Article
Molecular imaging of PD-L1 expression and dynamics with the adnectin-based PET tracer <sup>18</sup>F BMS-986192.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.241364
- By:
- Publication type:
- Article
Development and evaluation of interleukin-2 derived radiotracers for PET imaging of Tcells in mice.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.238782
- By:
- Publication type:
- Article
Assessment of Bone Lesions with <sup>18</sup>F-FDG-PET Compared to <sup>99m</sup>Technetium Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.244640
- By:
- Publication type:
- Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.241877
- By:
- Publication type:
- Article
Molecular imaging of PD-L1 expression and dynamics with the adnectin-based PET tracer <sup>18</sup>F- BMS-986192.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.241364
- By:
- Publication type:
- Article
Development and evaluation of interleukin-2 derived radiotracers for PET imaging of T-cells in mice.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.238782
- By:
- Publication type:
- Article
Assessment of Bone Lesions with 18F-FDG-PET Compared to 99mTechnetium Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.244640
- By:
- Publication type:
- Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.241877
- By:
- Publication type:
- Article